SIGA Technologies Logo Vector
SIGA Technologies, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for infectious diseases that pose significant public health threats. The company's lead product candidate, TAVPIC, is an investigational oral antiviral in development for the treatment of smallpox, a rare but highly contagious and deadly viral disease. SIGA is also developing other antiviral product candidates for the treatment of other infectious diseases, including COVID-19 and monkeypox.
